In vitro maturation of oocytes from excised ovarian tissue in a patient with autoimmune ovarian insufficiency possibly associated with Epstein-Barr virus infection
Some reports show that it is possible to isolate immature oocytes from human ovarian tissue retrieved by a cortex biopsy or ovariectomy of non-stimulated ovaries and mature them in vitro. The mature oocytes can be vitrified and stored for in vitro fertilization, which, along with ovarian tissue cryopreservation, is mostly practiced in young cancer patients to preserve their fertility. There is much less data on this new approach in women with a natural ovarian insufficiency, which can be caused by different factors, including viral infection. In this case report this advanced methodology was used in a young patient suffering from ovarian insufficiency which was possibly associated with Epstein-Barr virus and infectious mononucleosis (glandular fever).
This case report included a 27-year-old patient who attended our infertility clinic because of ovarian failure as a part of autoimmune polyendocrinopathy that occurred after Epstein-Barr virus infection, which has rarely been reported until now. Although antral follicles were observed in her ovaries by ultrasound monitoring, she was amenorrhoeic with menopausal concentrations of follicle-stimulating hormone (FSH) and without mature follicles. Therefore, a small biopsy of ovarian cortex tissue was performed using laparoscopy to retrieve immature oocytes. The retrieved oocytes were matured in vitro, cryopreserved, and stored for in vitro fertilization and potential pregnancy.
Four immature, germinal vesicle (GV) oocytes were found and removed from tissue, denuded mechanically by a pipette, and matured in vitro in a maturation medium with added FSH and hCG as well as in co-culture with cumulus cells, which were retrieved by their denudation. Three oocytes matured in vitro to the metaphase II (MII) stage and were vitrified for in vitro fertilization along with ovarian tissue cryopreservation.
Our results show that Epstein-Barr infection is possibly associated with autoimmune ovarian failure. The devastating impact on fertility in such disorder can be successfully avoided by in vitro maturation of oocytes from excised ovarian tissue.
KeywordsCase report Epstein-Barr virus In vitro maturation Laparoscopic biopsy Oocyte Ovarian failure Vitrification
Germinal vesicle (immature oocyte)
Human chorionic gonadotropin
In vitro maturation
Metaphase II stage (mature oocyte)
Premature ovarian failure
Recent reports have demonstrated that it is possible to isolate antral follicles and immature oocytes from human ovarian tissue retrieved by a cortex biopsy or ovariectomy of non-stimulated ovaries and mature them in vitro [1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]. The retrieved oocytes, which mature in vitro, can be vitrified and stored for in vitro fertilization. This is mostly practiced in young cancer patients, including those with borderline ovarian cancer , progressed ovarian cancer , and endometrial carcinoma , who cryostore their ovarian tissue before chemo- and radiotherapy to preserve their fertility. This cancer treatment is quite advanced and enhances the long-term survival of patients.
In vitro maturation and vitrification of oocytes retrieved from non-stimulated ovaries is usually performed along with ovarian tissue cryopreservation, which is performed to restore fertility by autotransplantation of tissue after cancer therapy . It is less complicated and safer to preserve fertility in this way than autotransplantation of ovarian tissue, which cannot completely exclude the reintroduction of malignant cells into the body; future transplantation of ovarian tissue is not recommended for several cancer types, such as leukemia, due to high risks of reintroducing malignant cells [17, 18, 19]. There are also some reports on the in vitro maturation and cryopreservation of oocytes retrieved from intra-operative aspiration during cancer surgery (e.g., second enucleation of ovarian tumors) .
It has been shown that a significant number of immature oocytes can be collected from excised ovarian tissue regardless of the menstrual cycle phases and age of the patient, even for prepubertal girls . Recent findings show that it is possible to isolate immature oocytes even from surplus ovarian medulla tissue and to mature them in vitro [21, 22]. Moreover, first pregnancies and the birth of a healthy baby achieved in this way have been reported recently, which make this new technology beneficial and promising for oncological patients and infertile women [12, 13, 14]. This new methodology can also be supported by advanced preimplantation and prenatal genetic testing.
There is not much data on this new approach in women who are infertile because of a natural ovarian insufficiency except for mosaic Turner syndrome  and an insufficiency following therapeutic embolization of the left uterine and right ovarian artery because of an arteriovenous malformation . This case report included a 27-year-old patient who attended our infertility clinic because of premature ovarian failure (POF) which was possibly associated with Epstein-Barr virus and infectious mononucleosis (glandular fever). Epstein-Barr virus is rarely related to female infertility in the literature ; it may be related to altered immunophenotypic parameters and peripheral immunostimulation in women with a history of infertility .
The 27-year-old patient was referred to our institution by her endocrinologist due to typical signs and symptoms of POF as a part of an autoimmune polyendocrinopathy that occurred after Epstein-Barr virus infection 3 years ago. At that time, she did not desire to become pregnant, but planned to conceive in the next couple of years. In addition to POF, she had Addison’s disease and thrombocytopenia, but normal thyroid function. For the last 2 years, she has not received hormonal replacement therapy (HRT); she was amenorrhoeic with menopausal concentrations of FSH (82.5 IU/L and 99.7 IU/L, respectively). Vaginal ultrasound examination 3 months after HRT (combination of estradiol valerate 2 mg and norgestrel 0.5 mg) withdrawal revealed a normal ovarian appearance with more than 10 antral follicles in each ovary without a dominant follicle. Genetic testing showed normal female karyotype and no fragile X-associated ovarian insufficiency (FXOI).
To retrieve ovarian tissue with possible immature oocytes, mature them in vitro, and vitrify them to perform a later in vitro fertilization along with ovarian tissue cryopreservation, laparoscopy was performed. During laparoscopy, the ovaries were normal in size with small follicles throughout the surface. With cold endoscopic scissors, a 10 × 5 mm section of the ovarian cortex was excided from each ovary opposite to the ovarian hilum. After washing the ovaries, hemostasis was achieved by placing a suture on the defect without using any thermal energy. The ovarian cortex tissue was stored in a sterile physiological saline (B. Braun, Melsungen AG, Germany) at room temperature and immediately brought into the laboratory to find possible immature oocytes, mature them in vitro, and vitrify them to perform a later in vitro fertilization along with ovarian tissue cryopreservation. At the same time a small specimen of each ovarian tissue was taken for histopathological examination. Pathology report showed active parenchyma of the right ovary with some primordial follicles and ovarian parenchyma of the left ovary with numerous primordial and some primary follicles.
This was approved by the Slovenian National Medical Ethical Committee (approval 0120–222/2016–2, KME 115/04/16), and the patient provided informed consent for voluntary participation.
A section of ovarian tissue was transferred to the IVF Laboratory, placed into Universal IVF Medium (Origio, Denmark), minced by a surgical blade (Tro-Microcision, Troge, Germany) and searched for follicles and oocytes. All oocytes were removed from tissue and denuded mechanically by a denudation pipette with a diameter of 134–145 μm and length 75–85 mm (ref. 14,301, Vitrolife, Sweden). Surrounding follicular cells with predominating granulosa cells were removed easily and stored for co-culture during the in vitro maturation procedure to provide an ovarian niche to some extent. The remaining ovarian cortex tissue was cut into smaller pieces and cryopreserved using a propanediol as a cryoprotectant and finally stored in liquid nitrogen (− 196 °C) to perform in vitro activation of follicles and autotransplantation of ovarian tissue beneath the serosa of both fallopian tubes in the future .
Oocyte in vitro maturation
For the maturation of oocytes, the certified MediCult IVM System (Origio, Målov, Denmark) was used, which consisted of two solutions: 1.) LAG medium (conditioning) and 2.) in vitro maturation (IVM) medium, which consisted of 100 μl of recFSH solution (75 mIU/ml; Puregon, Merck Sharp & Dohme Gmbh, Haar, Germany), 10 μl of hCG solution (100 mIU/ml; Pregnyl, Organon, Oss, Netherland) and 10 ml of basic IVM medium. Each oocyte was separately matured in a 60 μm drop of maturation medium covered by mineral oil in a UGPS-500 dish (Universal GPS® dish, LifeGlobal Group, Guilford, CT 06437, USA) at 37 °C in an atmosphere of air with 6% CO2 and 95% humidity. First, they were incubated for 2–3 h in the LAG medium and then for up to 48 h in the maturation medium with added FSH and hCG. Oocytes were co-cultured with granulosa cells retrieved by the previous denudation of oocytes to provide an ovarian niche to some extent; in usual practice, denuded human oocytes are matured in vitro without a granulosa cell co-culture.
Our data show that infection with Epstein-Barr virus, also known as human herpesvirus 4, possibly triggered the polyendocrinopathy (most likely autoimmune) including POF. The devastating impact on fertility in such disorder can be successfully avoided by in vitro maturation of oocytes from excised ovarian tissue.
Ovarian insufficiency or premature ovarian failure (POF) is characterized by loss of function of the ovaries before age 40 characterized with amenorrhoea, hypergonadotropism and hypoestrogenism being one of the most serious causes of infertility . It affects approximately one out of 100 women. Only 5–10% of women diagnosed with POF can achieve a spontaneous pregnancy, while most of them require medical intervention . There is no generally accepted treatment to increase fertility in women with ovarian insufficiency, and the use of donor eggs with in vitro fertilization (IVF) and adoption remain the only options for achieving parenthood for women with POF. The etiology of ovarian insufficiency is still poorly understood, and most cases remain unexplained. According to our data the infection with Epstein-Barr virus with infectious mononucleosis (glandular fever) and autoimmune polyendocrinopathy is considered to be a potential trigger of ovarian failure.
The majority of the human adult population is infected with Epstein-Barr virus, and the majority of infected individuals tolerate the infection well, without any further symptoms after primary infection . Normally, the virus stays in the body and remains dormant throughout life. However, this is not always the case, and a serious Epstein-Barr virus-related illness may develop later in life, especially different autoimmune diseases, such as systemic lupus erythematosus, multiple sclerosis, rheumatoid arthritis, Sjögren’s syndrome, autoimmune hepatitis, and autoimmune thyroid disorders . Although this virus is not the only agent responsible for the development of autoimmune diseases, it can be considered to be the main contributory factor.
According to our knowledge, there is not much data on the association between Epstein-Barr virus infection and autoimmune ovarian insufficiency in the literature, but POF is quite frequently associated with Addison’s disease which can be in rare cases caused by the virus [30, 31, 32].
The patient included in this study had primordial and primary follicles in her ovaries, which did not mature and produce mature oocytes. By performing in vitro maturation of oocytes from excised ovarian tissue, we avoided an autoimmune disorder and cryopreserved the mature oocytes for a later in vitro fertilization along with ovarian tissue cryopreservation. This approach can be beneficial also for other patients with autoimmune POF and non-maturing follicles/oocytes in the ovaries to preserve their fertility, while it cannot help patients with POF and without follicles in the ovaries. The most limiting factor is conventional oocyte in vitro maturation procedure in the presence of reproductive hormones only, which is suboptimal and results in a relatively low number of matured oocytes. Therefore the maturating oocytes in this patient were co-cultured with cumulus cells to provide an ovarian niche as well as with substances released by cumulus cells, which are important for human oocyte maturation  and are usually lacking when oocytes are matured in vitro in a conventional way without a co-culture.
Infection with Epstein-Barr virus with severe infectious mononucleosis (glandular fever) and autoimmune polyendocrinopathy need to be considered to be possibly associated with ovarian failure. Further histological, animal and molecular studies will be required for a final conclusion.
As in the patient included in this study, the ovaries of women with autoimmune POF need to be carefully examined for the presence of follicles because it is possible to isolate immature oocytes from excised ovarian tissue, mature them in vitro and vitrify and store them for a later in vitro fertilization along with ovarian tissue cryopreservation. The patient suffering with POF can safeguard her fertility by cryopreserving these excised oocytes. Co-culturing maturing oocytes with cumulus cells may be beneficial to provide an ovarian niche during the maturation process and improve the quality of matured oocytes.
We acknowledge the colleagues of Reproductive Unit, Department of Obstetrics and Gynecology, University Medical Centre Ljubljana for their collaboration.
This work was financially supported by the University Medical Centre Ljubljana as grant offered to Prof. Irma Virant-Klun (Tertiary Research Project No. 20150005).
Availability of data and materials
All data and materials from this case report are stored at the authors’ institution and are available from the authors upon reasonable request.
IVK performed the retrieval of oocytes from the excised ovarian tissue, maturation of oocytes in vitro, and cryopreservation of ovarian tissue; identified the results; and wrote this case report. AV performed the laparoscopical retrieval of ovarian cortex tissue, provided extended medical information to the patient, and edited this case report. Both authors read and approved the final manuscript.
Ethics approval and consent to participate
This study was approved by the Slovenian National Medical Ethical Committee (approval 0120–222/2016–2, KME 115/04/16), and the patient provided informed consent for voluntary participation.
Consent for publication
Written informed consent was obtained from the patient for the publication of these data and accompanying images.
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
- 5.Huang JY, Tulandi T, Holzer H, Lau NM, Macdonald S, Tan SL, et al. Cryopreservation of ovarian tissue and in vitro matured oocytes in a female with mosaic Turner syndrome: case report. Hum Reprod. 2008;23:336–9.Google Scholar
- 11.Shirasawa H, Kumagai J, Sato W, Kumazawa Y, Sato N, Terada Y. Retrieval and in vitro maturation of human oocytes from ovaries removed during surgery for endometrial carcinoma: a novel strategy for human oocyte research. J Assist Reprod Genet. 2013;30:1227–30.CrossRefPubMedPubMedCentralGoogle Scholar
- 13.Segers I, Mateizel I, Van Moer E, Smitz J, Tournaye H, Verheyem G, et al. In vitro maturation (IVM) of oocytes recovered from ovariectomy specimens in the laboratory: a promising “ex vivo” method of oocyte cryopreservation resulting in the first report of an ongoing pregnancy in Europe. J Assist Reprod Genet. 2015;32:1221–31.CrossRefPubMedPubMedCentralGoogle Scholar
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.